Single Photon Emission Computerized Tomography With Capromab Pendetide Plus Computerized Tomography Image Set Co-Registration Independently Predicts Biochemical Failure

Rodney J. Ellis, E. H. Zhou, P. Fu, D. A. Kaminsky, D. B. Sodee, P. F. Faulhaber, D. Bodner, M. I. Resnick

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: We evaluate the usefulness of pretreatment 111 Indium capromab pendetide (ProstaScint™) planar imaging (immunoscintigraphy) plus single photon emission tomography co-registration with computerized tomography scans to detect occult metastatic disease and predict for biochemical failure, in a cohort of patients with a clinical diagnosis of localized adenocarcinoma of the prostate referred for primary radiotherapy. Materials and Methods: Patients were followed after radiotherapy for evidence of biochemical failure using 2 criteria of prostate specific antigen clinical nadir +2 ng/ml and American Society for Therapeutic Radiology and Oncology Consensus definitions. Median followup was 58.8 months (mean 64.8). Clinical risk factors defined 3 risk groups of high (51), intermediate (72) and low (116). Results: Overall biochemical failure was 18.3% vs 11.8% by the 2-BFC at 8-year actuarial analysis with 58.8 months median followup. By the CN +2 definition the control date for the cohort is 34.8 months. Pretreatment SPECT/CT suggested prostate cancer metastasis (22), seminal vesicle extension (20) and organ confined disease (197). Biochemical failure in patients having extra-periprostatic metastatic prostate cancer, seminal vesicle extension and organ confined disease uptake on SPECT/CT was 43.2%, 16.0% vs 14.7% (p = 0.0006); and 33.3%, 15.0% vs 8.7% (p = 0.0017) by the 2-BFC, respectively. Cox multiple regression analysis demonstrated that a finding of extra-periprostatic metastatic prostate on SPECT/CT significantly predicted a 4.2-fold greater risk (p = 0.0012) and a 4.5-fold greater risk (p = 0.0011) of failure by the 2-BFC than organ confined disease adjusting for treatment and risk group. Conclusions: Unconfirmed findings of extra-periprostatic metastatic prostate cancer on SPECT/CT immunoscintigraphy independently and significantly predicted an increased risk of biochemical failure in patients presenting for radiotherapy with a clinical diagnosis of localized prostate cancer.

Original languageEnglish (US)
Pages (from-to)1768-1774
Number of pages7
JournalJournal of Urology
Volume179
Issue number5
DOIs
StatePublished - May 1 2008

Fingerprint

Single-Photon Emission-Computed Tomography
Tomography
Prostatic Neoplasms
Radiotherapy
Seminal Vesicles
Prostate
Actuarial Analysis
Indium
Prostate-Specific Antigen
Photons
Adenocarcinoma
Regression Analysis
Capromab Pendetide
Neoplasm Metastasis
Single Photon Emission Computed Tomography Computed Tomography
Therapeutics

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Ellis, Rodney J. ; Zhou, E. H. ; Fu, P. ; Kaminsky, D. A. ; Sodee, D. B. ; Faulhaber, P. F. ; Bodner, D. ; Resnick, M. I. / Single Photon Emission Computerized Tomography With Capromab Pendetide Plus Computerized Tomography Image Set Co-Registration Independently Predicts Biochemical Failure. In: Journal of Urology. 2008 ; Vol. 179, No. 5. pp. 1768-1774.
@article{80d3b63650ee4d52a1fc077104298d64,
title = "Single Photon Emission Computerized Tomography With Capromab Pendetide Plus Computerized Tomography Image Set Co-Registration Independently Predicts Biochemical Failure",
abstract = "Purpose: We evaluate the usefulness of pretreatment 111 Indium capromab pendetide (ProstaScint™) planar imaging (immunoscintigraphy) plus single photon emission tomography co-registration with computerized tomography scans to detect occult metastatic disease and predict for biochemical failure, in a cohort of patients with a clinical diagnosis of localized adenocarcinoma of the prostate referred for primary radiotherapy. Materials and Methods: Patients were followed after radiotherapy for evidence of biochemical failure using 2 criteria of prostate specific antigen clinical nadir +2 ng/ml and American Society for Therapeutic Radiology and Oncology Consensus definitions. Median followup was 58.8 months (mean 64.8). Clinical risk factors defined 3 risk groups of high (51), intermediate (72) and low (116). Results: Overall biochemical failure was 18.3{\%} vs 11.8{\%} by the 2-BFC at 8-year actuarial analysis with 58.8 months median followup. By the CN +2 definition the control date for the cohort is 34.8 months. Pretreatment SPECT/CT suggested prostate cancer metastasis (22), seminal vesicle extension (20) and organ confined disease (197). Biochemical failure in patients having extra-periprostatic metastatic prostate cancer, seminal vesicle extension and organ confined disease uptake on SPECT/CT was 43.2{\%}, 16.0{\%} vs 14.7{\%} (p = 0.0006); and 33.3{\%}, 15.0{\%} vs 8.7{\%} (p = 0.0017) by the 2-BFC, respectively. Cox multiple regression analysis demonstrated that a finding of extra-periprostatic metastatic prostate on SPECT/CT significantly predicted a 4.2-fold greater risk (p = 0.0012) and a 4.5-fold greater risk (p = 0.0011) of failure by the 2-BFC than organ confined disease adjusting for treatment and risk group. Conclusions: Unconfirmed findings of extra-periprostatic metastatic prostate cancer on SPECT/CT immunoscintigraphy independently and significantly predicted an increased risk of biochemical failure in patients presenting for radiotherapy with a clinical diagnosis of localized prostate cancer.",
author = "Ellis, {Rodney J.} and Zhou, {E. H.} and P. Fu and Kaminsky, {D. A.} and Sodee, {D. B.} and Faulhaber, {P. F.} and D. Bodner and Resnick, {M. I.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1016/j.juro.2008.01.025",
language = "English (US)",
volume = "179",
pages = "1768--1774",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

Single Photon Emission Computerized Tomography With Capromab Pendetide Plus Computerized Tomography Image Set Co-Registration Independently Predicts Biochemical Failure. / Ellis, Rodney J.; Zhou, E. H.; Fu, P.; Kaminsky, D. A.; Sodee, D. B.; Faulhaber, P. F.; Bodner, D.; Resnick, M. I.

In: Journal of Urology, Vol. 179, No. 5, 01.05.2008, p. 1768-1774.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Single Photon Emission Computerized Tomography With Capromab Pendetide Plus Computerized Tomography Image Set Co-Registration Independently Predicts Biochemical Failure

AU - Ellis, Rodney J.

AU - Zhou, E. H.

AU - Fu, P.

AU - Kaminsky, D. A.

AU - Sodee, D. B.

AU - Faulhaber, P. F.

AU - Bodner, D.

AU - Resnick, M. I.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Purpose: We evaluate the usefulness of pretreatment 111 Indium capromab pendetide (ProstaScint™) planar imaging (immunoscintigraphy) plus single photon emission tomography co-registration with computerized tomography scans to detect occult metastatic disease and predict for biochemical failure, in a cohort of patients with a clinical diagnosis of localized adenocarcinoma of the prostate referred for primary radiotherapy. Materials and Methods: Patients were followed after radiotherapy for evidence of biochemical failure using 2 criteria of prostate specific antigen clinical nadir +2 ng/ml and American Society for Therapeutic Radiology and Oncology Consensus definitions. Median followup was 58.8 months (mean 64.8). Clinical risk factors defined 3 risk groups of high (51), intermediate (72) and low (116). Results: Overall biochemical failure was 18.3% vs 11.8% by the 2-BFC at 8-year actuarial analysis with 58.8 months median followup. By the CN +2 definition the control date for the cohort is 34.8 months. Pretreatment SPECT/CT suggested prostate cancer metastasis (22), seminal vesicle extension (20) and organ confined disease (197). Biochemical failure in patients having extra-periprostatic metastatic prostate cancer, seminal vesicle extension and organ confined disease uptake on SPECT/CT was 43.2%, 16.0% vs 14.7% (p = 0.0006); and 33.3%, 15.0% vs 8.7% (p = 0.0017) by the 2-BFC, respectively. Cox multiple regression analysis demonstrated that a finding of extra-periprostatic metastatic prostate on SPECT/CT significantly predicted a 4.2-fold greater risk (p = 0.0012) and a 4.5-fold greater risk (p = 0.0011) of failure by the 2-BFC than organ confined disease adjusting for treatment and risk group. Conclusions: Unconfirmed findings of extra-periprostatic metastatic prostate cancer on SPECT/CT immunoscintigraphy independently and significantly predicted an increased risk of biochemical failure in patients presenting for radiotherapy with a clinical diagnosis of localized prostate cancer.

AB - Purpose: We evaluate the usefulness of pretreatment 111 Indium capromab pendetide (ProstaScint™) planar imaging (immunoscintigraphy) plus single photon emission tomography co-registration with computerized tomography scans to detect occult metastatic disease and predict for biochemical failure, in a cohort of patients with a clinical diagnosis of localized adenocarcinoma of the prostate referred for primary radiotherapy. Materials and Methods: Patients were followed after radiotherapy for evidence of biochemical failure using 2 criteria of prostate specific antigen clinical nadir +2 ng/ml and American Society for Therapeutic Radiology and Oncology Consensus definitions. Median followup was 58.8 months (mean 64.8). Clinical risk factors defined 3 risk groups of high (51), intermediate (72) and low (116). Results: Overall biochemical failure was 18.3% vs 11.8% by the 2-BFC at 8-year actuarial analysis with 58.8 months median followup. By the CN +2 definition the control date for the cohort is 34.8 months. Pretreatment SPECT/CT suggested prostate cancer metastasis (22), seminal vesicle extension (20) and organ confined disease (197). Biochemical failure in patients having extra-periprostatic metastatic prostate cancer, seminal vesicle extension and organ confined disease uptake on SPECT/CT was 43.2%, 16.0% vs 14.7% (p = 0.0006); and 33.3%, 15.0% vs 8.7% (p = 0.0017) by the 2-BFC, respectively. Cox multiple regression analysis demonstrated that a finding of extra-periprostatic metastatic prostate on SPECT/CT significantly predicted a 4.2-fold greater risk (p = 0.0012) and a 4.5-fold greater risk (p = 0.0011) of failure by the 2-BFC than organ confined disease adjusting for treatment and risk group. Conclusions: Unconfirmed findings of extra-periprostatic metastatic prostate cancer on SPECT/CT immunoscintigraphy independently and significantly predicted an increased risk of biochemical failure in patients presenting for radiotherapy with a clinical diagnosis of localized prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=41849109792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849109792&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2008.01.025

DO - 10.1016/j.juro.2008.01.025

M3 - Article

VL - 179

SP - 1768

EP - 1774

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -